详情页 - 云南省第一人民医院机构库

当前位置：首页 > 详情页

Daratumumab, Venetoclax, and Azacitidine in Combination with HAA Regimen as Consolidation Chemotherapy for T-cell Acute Lymphoblastic Leukemia with High CD38 Expression

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]The Sixth Affiliated Hospital, Kunming Medical University, Yunnan, China. [2]The 920th Hospital of Joint Logistics Support Force, Department of Hematology, Yunnan, China. [3]The People's Hospital of Yuxi City, Department of Hematology, Yunnan, China. [4]Kunming Medical University, School of General Practitioners, Yunnan, China. [5]The First People's Hospital of Yunnan Province, Department of Integrated TCM & Western Medicine, Yunnan, China.

出处：

DOI：

ISSN：

摘要：

To the Editor The combination of Venetoclax (Ven) and Azacitidine (Aza) may be effective for relapsed or refractory T-ALL (R/R TALL) [i,ii]. Researchers are exploring the use of Ven and/or Aza with AML-like chemotherapy regimens (e.g., HAG,CAG, FAI) for R/R T-ALL, including ETP and non-ETP subtypes [iii,iv,v]. The HAA regimen, composed of homoharringtonine (HHT), cytarabine (Ara-C), and Aclarubicin (Acla), has been commonly used in AML induction and salvage chemotherapy [vi,vii,viii] . We hypothesize that combining Ven and Aza with the HAA regimen (VA-HAA) may also exhibit therapeutic effects on T-ALL.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2025]版：

无

最新[2025]版：

大类 | 4 区医学

小类 | 4 区血液学

第一作者：

第一作者机构： [1]The Sixth Affiliated Hospital, Kunming Medical University, Yunnan, China. [2]The 920th Hospital of Joint Logistics Support Force, Department of Hematology, Yunnan, China. [3]The People's Hospital of Yuxi City, Department of Hematology, Yunnan, China. [4]Kunming Medical University, School of General Practitioners, Yunnan, China.

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：